AI Model Developed by Brigham Researchers Could Help Screen for Heart Defect
The AI model was more efficient at detecting signatures of atrial septal defect (ASD) in electrocardiograms (ECG) than traditional methods. (Source: BWH News)
Source: BWH News - August 17, 2023 Category: Hospital Management Source Type: news

Can Patent Foramen Ovales Cause Problems?
Discussion During fetal development, the heart primum and secundum septa grow and overlap leaving a small but important channel between the two atria. The foramen ovale is a flap valve moving blood from the right atrium into the left atrium directly and bypassing the high pressure pulmonary system. After birth and breathing air, the neonate’s lungs open up and the pulmonary vascular resistance decreases. The left atrium now has a relatively higher pressure than the right atria, and therefore pressure on the flap valve closes the foramen ovale. Usually within 6-12 months, the fusion of the primum and secundum of the f...
Source: PediatricEducation.org - July 24, 2023 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

How Does Ebstein ’ s Anomaly Present?
Discussion Ebstein’s anomaly (EA) accounts for about 0.3-0.5% of all congenital heart disease and about 40% of all tricuspid valve (TV) pathologies. It was first described by Dr. William Ebstein in 1866. In EA’s simplest form, the TV is displaced inferiorly from the normal hinge points into the right ventricle (RV). This is caused by delamination of both the septal and mural leaflets and they usually form a combined leaflet which can be more adherent to the RV. These anatomical changes causes poor movement of the leaflet(s) and tricuspid regurgitation. Displacement inferiorly can cause decreased RV capacity and...
Source: PediatricEducation.org - March 13, 2023 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

How Serious Is Atrial Septal Defect (ASD)?
Title: How Serious Is Atrial Septal Defect (ASD)?Category: Diseases and ConditionsCreated: 12/10/2021 12:00:00 AMLast Editorial Review: 6/9/2022 12:00:00 AM (Source: MedicineNet Kids Health General)
Source: MedicineNet Kids Health General - June 9, 2022 Category: Pediatrics Source Type: news

atHeart Medical Receives FDA Approval for the Second Phase of the ASCENT ASD U.S. IDE Trial
Company's reSept™ ASD Occluder Aims to Evolve Septal Closure with its Novel Metal-Free Frame Design BAAR, Switzerland and SANTA CLARA, Calif., Feb. 8, 2022 -- (Healthcare Sales & Marketing Network) -- atHeart Medical, a medical device company dedicated... Devices, Interventional, Cardiology, FDA atHeart Medical, reSept ASD Occluder, atrial septal defect (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 8, 2022 Category: Pharmaceuticals Source Type: news

atHeart Medical Appoints Seasoned Medtech Executive Andrew Cleeland to Board of Directors
BAAR, Switzerland and MOUNTAIN VIEW, Calif., Sept. 8, 2021 -- (Healthcare Sales & Marketing Network) -- atHeart Medical, a medical device company dedicated to establishing the new standard of care for closure of atrial septal defects (ASD), today announce... Devices, Cardiology, Personnel atHeart Medical, reSept ASD Occluder, atrial septal defect (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 8, 2021 Category: Pharmaceuticals Source Type: news

First Five Patients Successfully Treated with atHeart Medical's Novel reSept(TM) Atrial Septal Defect Occluder in U.S. IDE Pivotal Trial
The first occluder with a metal-free, bioresorbable frame for the treatment of patients with clinically significant, isolated ASDs BAAR, Switzerland and MOUNTAIN VIEW, Calif., July 14, 2021 -- (Healthcare Sales & Marketing Network) -- atHeart Medical, ... Devices, Interventional, Cardiology atHeart Medical, reSept ASD Occluder, atrial septal defect (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 14, 2021 Category: Pharmaceuticals Source Type: news

Newly Formed Company, atHeart Medical, Aims to Evolve Septal Closure with the reSept(TM) ASD Occluder
Company prepares for U.S. IDE clinical trial of its novel metal-free frame designed to reduce complications and preserve long-term treatment options BAAR, Switzerland and MOUNTAIN VIEW, Calif., April 20, 2021 -- (Healthcare Sales & Marketing Network) -... Devices, Interventional, Cardiology atHeart Medical, reSept ASD Occluder, atrial septal defect (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 20, 2021 Category: Pharmaceuticals Source Type: news

Results from the MITHRAS trial reported at TCT Connect and published in Circulation
(Cardiovascular Research Foundation) The MITHRAS randomized clinical trial found that interventional closure of an iatrogenic atrial septal defect (iASD) driven by transcatheter mitral valve repair (TMVR) was not superior to conservative medical treatment with regard to the primary endpoint of change in six-minute walking distance. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 15, 2020 Category: International Medicine & Public Health Source Type: news

What Are the Main Acyanotic Congenital Heart Diseases?
Discussion Congenital heart diseases (CHD) are malformations of the heart and great vessels. It occurs in about 5-8/1000 live births. Cyanotic congenital heart disease is often noted perinatally because of cyanosis, respiratory distress and/or poor feeding or other distress type problems. A review can be found here. Acyanotic congenital heart disease (ACHD) can present at birth but often is seen in older children or adults unless the lesions are severe, especially obstructive lesions. Severe lesions may also cause cyanosis and distress type problems in patients also. Shunting lesions cause problems by diverting blood flo...
Source: PediatricEducation.org - August 17, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Carag Receives U.S. FDA IDE Approval to Conduct Clinical Study of First Transcatheter Septal Occluder With Bioresorbable, Metal-free Framework
The U.S. trial for CE-marked CBSO is designed to enroll up to 250 patients in a staged study approach BAAR, Switzerland, July 1, 2020 -- (Healthcare Sales & Marketing Network) -- CARAG AG, a privately-held Swiss medical device development company, toda... Devices, Interventional, Cardiology, FDA Carag AG, Carag Bioresorbable Septal Occluder, atrial septal defects (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 1, 2020 Category: Pharmaceuticals Source Type: news

What Causes Bradycardia?
Discussion Bradycardia is a heart rate below what the lowest value that is normal for age. Infants and children have higher heart rates that slowly decrease with age to adult levels. It is usually noted as an incidental finding because of increased vagal tone. Reasons for cardiology referral include associated heart murmur, syncope especially if associated with exercise or unusual triggers, other signs such as chest pain or palpitations, family history of sudden cardiac death, congenital heart disease or familial heart disease, bradycardic medication use, or unusual symptoms associated with the concern. Severe bradycardia ...
Source: PediatricEducation.org - June 22, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

GORE(R) CARDIOFORM ASD Occluder Receives FDA Approval for the Treatment of Atrial Septal Defects
Data from the Gore ASSURED Clinical Study demonstrated 100 percent closure success at six months FLAGSTAFF, Ariz., June 4, 2019 -- (Healthcare Sales & Marketing Network) -- W. L. Gore & Associates (Gore) announced the U.S. Food and Drug Administration'... Devices, Interventional, Cardiology, FDA W. L. Gore, patent foramen ovale, CARDIOFORM, Septal Occluder (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 4, 2019 Category: Pharmaceuticals Source Type: news

Gore Takes on Abbott with New PFO Stroke Indication
W.L. Gore & Associates has received FDA approval to expand the indication of the Gore Cardioform Septal Occluder to reduce the risk of recurrent ischemic stroke in patients. The device treats patients through the closure of patent foramen ovale (PFO). Cardioform’s previous indication was for the closure of atrial septal defects that are up to 17mm in size. Gore’s Structural Heart Leader, Jake Goble said Cardioform has the potential to redefine stroke prevention. Goble began working for Gore in 2007. It was around that time the company began to explore the possibility of having the Cardioform focus on stroke prevent...
Source: MDDI - April 3, 2018 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Source Type: news

ESOC 2017 Roundup: Gore touts lowered ischemic stroke, new brain infarcts in PFO Occluder test
W.L. Gore & Associates yesterday released results from the Reduce study of its Cardioform Septal Occluder devices used to close patent foramen ovale, touting a reduction in recurrent ischemic strokes and new brain infarcts. The Gore Cardioform Septal Occluder is designed to be inserted via catheter and is currently cleared by the FDA for closure of atrial septal defects. “It is of the utmost importance to us to be transparent and share clinical data as quickly as possible. We completed our two-year primary endpoint follow-up with patients in March and have worked diligently to release these important data to the ...
Source: Mass Device - May 17, 2017 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Catheters Clinical Trials Stryker W.L. Gore & Associates Source Type: news